Abstract 15748: Alirocumab Efficacy and Safety by Race and Ethnicity: Analysis From Three ODYSSEY Phase 3 Trials

Background: Differences in lipids and cardiovascular disease risk profiles have been observed in African American/Black (AA/B) vs White (W), and Hispanic/Latino (H/L) of any race vs non-H/L populations. The efficacy and safety of alirocumab (ALI) may potentially vary by race and ethnicity and has not been analyzed in detail. Purpose: This post-hoc analysis evaluated the efficacy and safety of ALI vs control from ODYSSEY Phase 3 trials COMBO I, COMBO II and LONG TERM (LT) by race (AA/B or W) and ethnicity of any race (H/L or non/HL), both self-identified. Methods: Patients with elevated LDL-C despite maximally-tolerated statin received ALI (75 mg up to 150 mg every two weeks [Q2W] [COMBO II W: n=3039) and ethnicity (H/L: n=175; non-H/L: n=3197). Results: At baseline, LDL-C levels were similar across treatment...